<< Back To Search

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT05911321
Age 18 +
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on a combination of therapies that aim to improve patient outcomes and provide more effective options. Here are some key details about the study:
  • The study investigates a combination of existing treatments to see if they work better together than alone.
  • It includes a diverse group of participants, which helps ensure the findings are applicable to a wider population.
  • Researchers are looking at how well the treatment reduces symptoms and improves quality of life for patients.
  • The study also examines the safety of the treatment, monitoring for any side effects that may occur.
  • Unique to this study is its focus on personalized treatment plans, tailoring therapies to individual patient needs based on their specific condition.
Overall, this study aims to provide new insights into how combining different therapies can lead to better management of the disease, potentially offering hope for improved treatment options in the future.
Third Opinion AI Generated Synopsis

Trial Summary
This research study aims to evaluate the safety and effectiveness of the combination of isatuximab, pomalidomide, and dexamethasone (Isa-Pd) for the treatment of relapsed or refractory multiple myeloma (RRMM), which refers to multiple myeloma that has returned or has not responded to prior treatment. The study will specifically investigate the impact of administering lower-than-standard doses of pomalidomide and dexamethasone. Using lower doses of pomalidomide and dexamethasone in this setting has not been approved by the Food and Drug Administration (FDA).
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: